Enterprise Value
-7.186M
Cash
21.1M
Avg Qtr Burn
-4.444M
Short % of Float
1.76%
Insider Ownership
42.39%
Institutional Own.
7.40%
Qtr Updated
03/31/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
XEPI (ozenoxacin) Details Impetigo | Approved Quarterly sales | |
Ameluz (aminolevulinic acid hydrochloride) Details BCC (basal cell carcinoma), AK (actinic keratosis) | Approved Quarterly sales | |
BF-RhodoLED® XL combo w/ Ameluz® Details Actinic keratosis | Approved Quarterly sales | |
Ameluz® - PDT (3 tubes) Details Actinic keratosis | Phase 1 Data readout |